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ASK1 restores the antiviral activity of APOBEC3G
by disrupting HIV-1 Vif-mediated counteraction
Kei Miyakawa1, Satoko Matsunaga1, Kazuhiko Kanou2, Atsushi Matsuzawa3, Ryo Morishita1,4, Ayumi Kudoh1,
Keisuke Shindo5, Masaru Yokoyama6, Hironori Sato6, Hirokazu Kimura2, Tomohiko Tamura7, Naoki Yamamoto8,
Hidenori Ichijo3, Akifumi Takaori-Kondo5 & Akihide Ryo1
APOBEC3G (A3G) is an innate antiviral restriction factor that strongly inhibits the replication
of human immunodeﬁciency virus type 1 (HIV-1). An HIV-1 accessory protein, Vif, hijacks the
host ubiquitin–proteasome system to execute A3G degradation. Identiﬁcation of the host
pathways that obstruct the action of Vif could provide a new strategy for blocking viral
replication. We demonstrate here that the host protein ASK1 (apoptosis signal-regulating
kinase 1) interferes with the counteraction by Vif and revitalizes A3G-mediated viral
restriction. ASK1 binds the BC-box of Vif, thereby disrupting the assembly of the Vif–ubiquitin
ligase complex. Consequently, ASK1 stabilizes A3G and promotes its incorporation into viral
particles, ultimately reducing viral infectivity. Furthermore, treatment with the antiretroviral
drug AZT (zidovudine) induces ASK1 expression and restores the antiviral activity of A3G in
HIV-1-infected cells. This study thus demonstrates a distinct function of ASK1 in restoring the
host antiviral system that can be enhanced by AZT treatment.
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T
he innate immune system is an evolutionarily conserved
network that acts as a ﬁrst-line defense against invading
microbial pathogens and other potential threats to host
cells1. In addition to the nonspeciﬁc or broadly speciﬁc
counteraction exerted by the physiological component of
innate immunity, a more speciﬁc response is exerted by
intracellular restriction factors, which belong to a group of
interferon-stimulated genes2,3. When interferons induce their
transcription, restriction factors limit the replication of invading
viruses. One such factor is an editing enzyme for nucleic acids,
APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like 3G, hereafter referred to as A3G). This protein
severely restricts the replication of numerous viruses, including
human immunodeﬁciency virus type 1 (HIV-1)4 and hepatitis B
virus5, by extensively deaminating cytosine residues in the viral
genome during reverse transcription. This process introduces
unnatural (cytosine-to-uracil) mutations in the minus-strand
viral DNA, leading to either the destabilization of reverse
transcripts or the production of defective viral proteins6–8. In
addition, A3G appears to inhibit the elongation of reverse
transcripts by deaminase-independent mechanisms9,10.
Although A3G is a potent antiviral molecule, HIV-1 has
developed a speciﬁc accessory protein, Vif, which can counteract
the antiviral activity of A3G. In infected cells, Vif forms an
ubiquitin ligase complex with Cullin5 (CUL5), Elongin B/C
(ELOB/C) and CBFb that ubiquitinates and degrades A3G11–13.
In HIV-1 isolates lacking the Vif gene, A3G is efﬁciently
incorporated into virions by interacting with viral nucleocapsid
protein and viral RNA, severely limiting viral replication in the
target cells14,15. In addition, many studies using CD4þ
lymphocytes or humanized mice suggest that A3G activity is
crucial for inhibiting viral replication and pathogenesis4,16,17.
Thus, the strategies to promote A3G stability and its
incorporation into virions could be a new avenue for the
development of new antiviral drugs. In this regard, the disruption
of any of the steps required for the effect of Vif on A3G would be
expected to restore cellular A3G levels and virus restriction. This
concept has been validated in several reports that used a
ﬂuorescence-based screen to identify a small compound that
speciﬁcally inhibits the Vif–A3G interaction18–20. However, it is
still unclear if Vif is regulated by external or internal cellular
signalling and which cellular components are involved. Thus, the
identiﬁcation of host regulators of Vif may provide an alternative
therapeutic strategy for HIV-1 infection that preserves the
antiviral activity of the host defense system.
Here we demonstrate that apoptosis signal-regulating kinase 1
(ASK1) binds ‘hot spots’ within Vif to block its interaction with
components forming the ubiquitin ligase complex, resulting in
the stabilization of A3G and reactivation of A3G-mediated host
defense activity. We have therefore identiﬁed a novel host factor
governing the Vif–A3G interaction that directs the restoration of
the innate antiviral response.
Results
ASK1 binds and counteracts Vif. The mitogen-activated protein
(MAP) kinase signalling pathway can transduce extracellular
signals into regulatory events that impact the responses of cells to
such stimuli21. The kinase cascade eventually modulates the
cellular context, leading to the regulation of transcription factors
affecting gene expression. MAP3Ks are regarded as effectors of
the recognition of a variety of stimuli and activators of
intracellular signal transduction pathways22–24. We thus initially
determined whether MAP3K family members could affect the
Vif-mediated counteraction of A3G. HEK293 cells were
cotransfected with plasmids encoding Vif, green ﬂuorescent
protein (GFP)-A3G, and the indicated MAP3Ks, and then GFP
intensities were assessed with ﬂow cytometry and immunoblot
analysis. Notably, the expression of MAP3K5, also named ASK1,
maintained A3G expression, even in the presence of Vif
(Fig. 1a,b). Immunoprecipitation analysis showed that ASK1
interacted with Vif (Fig. 1c). This interaction was also conﬁrmed
by an in vitro protein–protein interaction assay with the ampliﬁed
luminescent proximity homogenous assay AlphaScreen25
(Fig. 1d). Moreover, the activation or suppression of ERK-,
p38- and JNK-mediated MAPK pathways did not alter the ability
of ASK1 to bind and counteract Vif (Supplementary Fig. 1a–c).
These results suggest that ASK1 directly binds Vif and suppresses
the action of Vif on A3G. We next sought to identify the binding
regions within Vif for its interaction with ASK1. As well as an
A3G-binding domain in the amino (N)-terminal half, Vif
contains an HCCH motif and a BC-box (SLQ motif) in the
carboxyl (C)-terminal half that are essential for interaction with
CUL5 and ELOB/C, respectively26,27. The N-terminal and central
domains of Vif are involved in binding CBFb12,27–29.
Immunoprecipitation experiments with truncated mutants of
Vif showed that ASK1 associated with all Vif mutants except the
VifD1 mutant lacking the BC-box (Fig. 1e). Notably, ASK1 failed
to interact with another BC-box-containing protein VHL (von
Hippel–Lindau)30 and did not affect the function of VHL in
downregulating hypoxia-inducible factor 1-a (Supplementary
Fig. 2a,b). This implied a speciﬁc interaction of ASK1 with
Vif. We next mapped the Vif-binding site within ASK1.
ASK1 contains a kinase domain in the central region and two
coiled-coil domains in the N- and C-terminal regions31.
Immunoprecipitation analysis with truncated mutants of ASK1
clearly showed that Vif binds the C-terminal (CT: 955–1,374
amino acids) domain of ASK1 (Fig. 1f). Our results thus
suggested that the ASK1 CT may interact with the BC-box of
HIV-1 Vif.
ASK1 inhibits the formation of Vif–E3 ubiquitin ligase com-
plex. We next assessed the functional and structural aspects of the
Vif–ASK1 interaction. Consistent with the results of our binding
analysis (Fig. 1f), ASK1 CT was sufﬁcient to inhibit Vif-mediated
A3G degradation, whereas an ASK1 DC mutant devoid of the
Vif-binding domain had lost this ability (Fig. 2a). To predict the
functional impact of the binding of ASK1 to Vif, we constructed
ASK1 CT structural models and docked them with the recently
solved Vif structure (PDB: 4N9F). Interestingly, our computa-
tional docking simulation data proposed a model whereby ASK1
CT interacts with the BC-box of Vif (Fig. 2b), consistent with our
immunoprecipitation results (Fig. 1e,f). This structural model also
predicted that ASK1 CT–Vif binding might partially interfere
with the association of Vif with ELOC (Fig. 2b). Indeed, Vif BC-
box mutants (S144A, L145A, and Q146A) that demonstrate
impaired binding of ELOC32, but not Vif mutants of other
potential ASK1-binding sites (R93, Y94, I124 and L125), failed to
interact with ASK1 (Fig. 2c, Supplementary Fig. 3). To further test
this hypothesis, we performed in vitro pull-down analysis with
recombinant versions of the proteins forming the Vif-mediated
E3 complex (CUL5, ELOB/C and CBFb) in the presence or
absence of ASK1. FLAG-tagged CUL5, ELOB/C and CBFb
proteins were mixed with biotin-labelled Vif and various amounts
of ASK1, and then Vif-interacting components were pulled-down
using streptavidin-coated beads (Fig. 2d). Subsequent
immunoblotting analysis demonstrated that ASK1 inhibited the
interaction of Vif with ELOB/C in a dose-dependent manner,
whereas no signiﬁcant change was observed in the binding of Vif
with either CUL5 or CBFb (Fig. 2d,e). Consistent with these
in vitro interaction data, our cell-based analysis further revealed
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that ASK1 reduced the E3 ligase activity of Vif (including the
autoubiquitination of Vif), which was accompanied by a
reduction in the Vif–ELOC interaction (Fig. 2f). Moreover,
ASK1 markedly reduced Vif ubiquitination of A3G (Fig. 2g).
Although Mehle et al.33 have reported previously that
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Figure 1 | ASK1 binds and counteracts Vif. (a,b) ASK1 inhibits Vif-mediated A3G degradation. HEK293 cells were cotransfected with plasmids encoding
Vif (250 ng), GFP-A3G (50ng) and the indicated HA-tagged MAP3Ks or Xpress (XP)-tagged ASK1 (500ng). After 48 h, GFP intensities (n¼ 3,
mean±s.d.), cell images and protein expression levels were analysed by ﬂow cytometry (a), ﬂuorescence microscopy and western blotting (b),
respectively. Scale bar, 100mm. (c) ASK1 interacts with Vif in cells. Cells were cotransfected with plasmids encoding ASK1-HA and Vif. Cell lysates were
immunoprecipitated with an anti-HA antibody and the bound proteins were then analysed by western blotting. (d) In vitro interaction of ASK1 with Vif.
Schematic representation of the ampliﬁed luminescent proximity homogeneous (AlphaScreen) assay used to detect the direct protein–protein interaction
(left). In this study, FLAG-tagged Vif proteins were co-expressed with CBFb to stabilize the conformation of the Vif protein28,63. AlphaScreen analysis
(n¼ 3, mean±s.d.) using recombinant ASK1, A3G and Vif proteins is shown (right). GST and DHFR (dihydrofolate reductase) were used as negative
controls. ***Po0.001, two-tailed unpaired t-test. (e) HEK293 cells were cotransfected with plasmids encoding ASK1-HA and Vif or one of its truncated
mutants (top). Cell lysates were immunoprecipitated with anti-HA antibody and bound Vif proteins were detected with western blot analysis (bottom).
(f) HEK293 cells were cotransfected with plasmids encoding Vif and ASK1-HA or one of its truncated mutants (top). Cell lysates were immunoprecipitated
with anti-HA antibody and bound Vif proteins were detected by western blot analysis (bottom). Full images for all western blots analysis are
shown in Supplementary Fig. 5.
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Vif–ELOB/C complex assembly, we could not detect any Vif
phosphorylation by ASK1 (Supplementary Fig. 4). Our data
suggest that ASK1 interacts with the BC-box motif of Vif and
inhibits the formation of the E3 complex by interfering with the
interaction between Vif and ELOB/C.
Nef does not affect ASK1-mediated Vif inactivation. Previous
studies have demonstrated that ASK1 potently associates with
Nef, another HIV accessory protein. Nef reduces the kinase
activity of ASK1 to prevent tumour necrosis factor-a- and FAS-
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Figure 2 | ASK1 inhibits the formation of Vif–E3 ubiquitin ligase complex. (a) The C-terminal domain (CT) of ASK1 is sufﬁcient to impair Vif-mediated
A3G degradation. HEK293 cells were cotransfected with plasmids encoding XP-ASK1 (500ng), HA-A3G (10ng) and Vif (50 or 100ng). Protein expression
was then detected using western blot analysis. The numerical values below the blot indicate the amounts of HA-A3G determined with densitometry. (b) The
structural model of ASK1 CT (yellow) was generated and subjected to docking simulation with Vif (green, PDB: 4N9F). ELOC (purple) was overlaid onto the
Vif–ASK1 model. The square shows the predicted inhibition by ASK1 of ELOC binding to the BC-Box of Vif. (c) The BC-box motif of Vif is important for the
binding of ASK1. HEK293 cells were cotransfected with plasmids encoding ASK1-HA and Vif or the indicated mutants. Cell lysates were immunoprecipitated
with anti-HA antibody and bound Vif proteins were detected by western blot analysis. (d,e) ASK1 inhibits the formation of the ubiquitin ligase complex by
blocking Vif interaction with ELOB/C. (d) Recombinant biotinylated Vif was co-synthesized with CBFb and then pre-mixed with various amounts of ASK1 for
5min before the addition of equivalent amounts of FLAG-tagged CUL5, ELOB and ELOC. After 1 h, the mixture was processed for pull down with streptavidin-
coated magnetic beads as shown on the left. Bound proteins were detected by western blot (right panels). The bar charts shown in e indicate the amounts of
Vif-associated proteins in the presence of ASK1, determined by densitometric analysis of the western blots (n¼ 3, mean±s.d.). **Po0.01, two-tailed
unpaired t-test. (f) HEK293 cells were cotransfected with plasmids encoding XP-ASK1, Vif and Myc-Ubiquitin (Ub). Cells were then treated with MG132 for
18 h before being harvested. Cell lysates were immunoprecipitated with anti-Vif antibody and the ligase activity of Vif was detected by western blot analysis
using an anti-Myc antibody. (g) HEK293 cells were cotransfected with plasmids encoding XP-ASK1, HA-A3G, Vif and Myc-Ub. Cells were then treated with
MG132 for 18 h before being harvested. Cell lysates were immunoprecipitated with anti-HA antibody and the Vif-induced ubiquitination of A3G was detected
by western blot analysis using anti-Myc antibody. Full images for all western blots analysis are shown in Supplementary Fig. 5.
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ASK1-mediated Vif inactivation. Immunoblotting analysis
revealed that Nef overexpression inhibited the autophos-
phorylation of ASK1 (phosphorylated Thr845 of ASK1), a
hallmark of its kinase activity (Fig. 3a). Notably, irrespective of
Nef expression, our data also showed that ASK1 effectively
inhibited Vif-mediated A3G degradation (Fig. 3b), suggesting
that the kinase activity of ASK1 is dispensable for its ability to
inhibit Vif. Moreover, a kinase-negative (K709M) mutant of
ASK1 also inhibited Vif-mediated A3G degradation, although a
constitutively kinase-active ASK1 (DN) mutant exhibited a
slightly higher ability to inhibit Vif via an unknown mechanism
(Fig. 3c,d). These results suggest that ASK1 kinase activity is
dispensable for, but has an additive effect in, inhibiting the
function of Vif. This is indicative of the involvement of multiple
mechanisms in the ASK1-mediated inhibition of Vif.
ASK1 restricts HIV-1 replication via A3G reactivation. To test
whether ASK1 regulates viral infectivity by interfering with Vif
function and stabilizing A3G, we performed a single-cycle viral
infection assay using HIV-1NL4-3 and its Vif-deﬁcient mutant
virus collected from ASK1-expressing cell supernatants. Immu-
noblotting analysis of cell lysates and viral supernatants revealed
that the expression of either ASK1 or its DN mutant suppressed
the Vif-mediated degradation of A3G in cells, increasing the
amount of A3G in virions to that seen with a Vif-deﬁcient virus
(Fig. 4a,b). Consistent with this result, the infectivity of viruses
harvested from either ASK1- or ASK1 DN-overexpressing cells
was much lower than that of control cells (Fig. 4c). Since the
endogenous ASK1 levels in T cells were nearly undetectable in the
normal state (Fig. 4d), we generated stable cell lines, CEM (A3G-
positive) and CEMSS (A3G-negative), harbouring a tetracycline-
inducible ASK1 gene, referred to hereafter as CEM-TetON-ASK1
and CEMSS-TetON-ASK1, respectively. Treatment with a tetra-
cyclic antibiotic, doxycycline (Dox), induced the expression of
ASK1 in both cell lines at the physiological levels seen in PMA-
treated 293 cells35 (Fig. 4d). Notably, Dox-induced ASK1
inhibited HIV-1 replication in CEM-TetON-ASK1 but not in
CEMSS-TetON-ASK1 cells (Fig. 4e). Moreover, immunoblotting
analysis demonstrated that the A3G level in virions was increased
only in Dox-treated CEM-TetON-ASK1 cells (Fig. 4f). In
addition, the number of G-to-A hypermutations in the viral
genomes was markedly increased in these cells (Fig. 4g). Taken
together, our data suggest that ASK1 restricts the replication of
HIV-1 by promoting A3G incorporation into virions in human
CD4þ T cells.
AZT induces ASK1 and promotes the antiviral activity of A3G.
Generally, MAP3Ks act as stress-responsive kinases that quickly
activate downstream cascades by sensing various stimuli such as
cytokines, hormones and anticancer drugs36. We wished to
evaluate the pathophysiological signiﬁcance of ASK1-mediated
antiviral activity. Initially, we assessed whether approved
antiretroviral drugs could induce ASK1 activity. Interestingly,
the reverse transcriptase inhibitors azidothymidine/zidovudine
(AZT) were found to induce ASK1 expression in peripheral blood














   (anti-Xpress)
– Nef-FLAG
– ASK1
   (anti-Xpress)
– Phospho-ASK1(T845)
   (anti-pASK1)
– Phospho-ASK1(T845)
   (anti-pASK1)
– –Nef-FLAG :
















+++ HA-A3G : +
+++++++++++ +






100 21 18 100 88 81 100 49 15 100 98 72
NoneXP-ASK1 :
A3G amounts (% of control)
A3G amounts (% of control)
Figure 3 | Nef does not affect ASK1-mediated Vif inactivation. (a) Nef inhibits the autophosphorylation of ASK1. HEK293 cells were cotransfected with
plasmids encoding XP-ASK1 (100 ng) and Nef-FLAG (100 or 200ng). Cell lysates were subjected to western blot analysis using the indicated antibodies.
(b) Nef does not alter the effect of ASK1 on Vif-mediated A3G degradation. HEK293 cells were cotransfected with plasmids encoding XP-ASK1 (500ng),
HA-A3G (10 ng), Vif (50 or 100ng) and Nef-FLAG (1 mg). Protein expression was detected by western blot. The numerical values below the blot indicate
the amounts of HA-A3G determined with densitometry. (c) HEK293 cells were transfected with the indicated ASK1 mutants (DN, constitutively active;
K709M, kinase-dead). Cell lysates were subjected to western blotting against the indicated antibodies. (d) HEK293 cells were cotransfected with plasmids
encoding HA-A3G (10 ng), Vif (50 or 100ng) and with wild-type ASK1 or one of its kinase mutants (500ng). Protein expression was detected by western
blot. The numerical values below the blot indicate the amounts of HA-A3G as determined by densitometry. Full images for all western blots analysis are
shown in Supplementary Fig. 5.
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(Fig. 5a,b). A previous report has indicated that the maximum
serum AZT concentration after oral administration is B10 mM
(ref. 37). We next assessed the possibility that AZT treatment at
physiological concentrations would activate the ASK1–A3G axis
in HIV-infected cells. H9 cells were transfected with either ASK1-
targeted short interfering RNA (siRNA) or control siRNA and
then infected with HIV. At 2 days after infection, the cells were
washed and additionally cultured for 24 h at the presence or
absence of AZT at 10 mM (Fig. 5c). In this experiment, we used an
AZT-resistant virus harbouring reverse transcriptase mutations
(T69G, K70R, L74I, K103N, T215F and K219Q)38,39 to minimize
the carry-over effect of AZT from the cell culture supernatants of
producer cells. We found that A3G incorporation into virions was
enhanced by transient AZT treatment of control cells, but this
was not the case in ASK1-depleted cells (Fig. 5c). In accordance
with the results for A3G amounts in virions, the infectivity of
viruses derived from AZT-treated cells was signiﬁcantly reduced;
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Figure 4 | ASK1 restricts HIV-1 replication via A3G reactivation. (a–c) ASK1 expression in virus-producing cells promotes A3G incorporation into virions
and reduces infectivity. HEK293 cells were cotransfected with an HIV-1 molecular clone carrying a GFP reporter gene (pNL4-3DEnv-GFP) or its Vif-deﬁcient
mutant (pNL4-3DEnvDVif-GFP) together with a plasmid encoding VSV-G, XP-ASK1 and HA-A3G. (a,b) Forty-eight hours after transfection, cell lysates and
supernatants were harvested and analysed by western blotting against the indicated antibodies. The bar chart in b indicates the amounts of HA-A3G
normalized by p24 levels in virions, as determined by densitometric analysis of western blots (n¼ 3, mean±s.d.). (c) The CD4þ T-cell line (M8166) was
infected with harvested and normalized virus for 2 days and infected (GFP-positive) cells were then measured by ﬂow cytometry (n¼ 3, mean±s.d.).
*Po0.05; **Po0.01, two-tailed unpaired t-test. (d) Expression levels of ASK1 in DOX-treated or untreated CEM-TetON-ASK1 and CEMSS-TetON-ASK1
cells. 293 cells transfected with ASK1 or treated with PMA are shown as positive controls. (e–g) CEM-TetON-ASK1 and CEMSS-TetON-ASK1 cells and their
parent cell lines (CEM and CEMSS) were infected with HIV-1. (e) Culture supernatants were harvested at the indicated time-points and subjected to p24
ELISA (n¼ 3, mean±s.d.). *Po0.05, two-tailed unpaired t-test. (f) The incorporation of A3G into virions from indicated cells (at 8 d.p.i.) was detected by
western blot. (g) The infected cells (CEM-TetON-ASK1) were harvested at 8 d.p.i. and subjected to G-to-A hypermutation analysis (n¼8, mean±s.d.).
**Po0.01, two-tailed unpaired t-test. Full images for all western blots analysis are shown in Supplementary Fig. 6. d.p.i., days post infection; ELISA, enzyme-
linked immunosorbent assay.
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cells (Fig. 5d). Taken together, our data show that AZT can
promote the antiviral activity of A3G by inducing ASK1.
Discussion
We here demonstrate that ASK1 is an AZT-inducible host factor
that negatively regulates the Vif-mediated degradation of A3G to
restore intrinsic antiviral immunity to HIV-1 (a proposed model
is depicted in Fig. 6). Since our preliminary studies have
suggested that several external stimuli can inhibit Vif-mediated
A3G degradation, we here targeted human protein kinases as
responders to the external stimuli that regulate the functionality
of Vif. A ﬂuorescence-based screen ultimately identiﬁed ASK1 as
acting as an ‘anti-Vif factor’ in terms of A3G protein stability.
Indeed, cells overexpressing ASK1 showed a restored A3G























































































Figure 5 | AZT induces ASK1 and promotes the antiviral activity of A3G. (a,b) PBMC or H9 cells were treated with the indicated agents (0–10mM) for
24 h. The expression of ASK1 was conﬁrmed by western blotting. APV, amprenavir; ATV, atazanavir; AZT, zidovudine; DRV, darunavir; IDV, indinavir; LPV,
lopinavir; NFV, nelﬁnavir; NVP, nevirapine; SQV, saquinavir; 3TC, lamivudine. (c) H9 cells were transfected with control siRNA or ASK1-targeted siRNA for
48 h before infection of HIV-1. At 2 days after infection, cells were washed and additionally cultured for 24 h in the presence or absence of AZT (10 mM).
Cells and supernatants were then harvested and analysed by western blotting against the indicated antibodies. We used AZT-resistant virus to avoid the
effects of AZTcarry-over from the culture supernatant of producer cells during the reverse transcription step in target cells. (d) TZM-bl reporter cells were
infected with harvested and normalized virus to measure viral infectivity (n¼ 3, mean±s.d.). Full images for all western blots analysis are shown in
Supplementary Fig. 6.

































Figure 6 | A proposed model for ASK1 enhancement of the antiviral activity of A3G. For efﬁcient viral replication, Vif targets A3G for ubiquitination and
proteasomal degradation by forming a stem cell factor-like E3 ubiquitin ligase complex composed of CUL5, ELOB/C and CBFb. External agents such as AZT
can induce ASK1 expression. ASK1 physically interacts with Vif and interferes with the formation of the Vif–E3 ubiquitin ligase complex. Consequently, the
antiviral activity of A3G is restored and the virus replication is inhibited. Although another HIV accessory protein, Nef, inhibits the kinase activity of ASK1,
this protein does not appear to alter the impact of ASK1 on Vif.
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the secondary infection. Our study ﬁndings thus shed new light
on the molecular link between ASK1 and Vif-mediated HIV-1
evasion of the host antiviral system and provide a better
understanding of the role of a pre-existing antiretroviral drug
in bolstering the host innate immune system.
Cellular regulatory mechanisms confer a sensitive, speciﬁc and
robust response to external stimuli and initiate certain molecular
events in cells. Such dynamic regulation is achieved through
post-translational modiﬁcations (PTMs) including phospho-
rylation and ubiquitination. PTMs offer a dynamic way to
regulate protein–protein interactions and protein activity,
subcellular localization and stability40. Thus, virus–host protein
interactions can also be modulated by PTMs as a response to
external stimuli such as chemicals, growth factors and cytokines.
In this regard, Mehle et al.33 reported that the phosphorylation of
Vif blocks assembly of the Vif–E3 complex. Moreover, the
NEDD8 ubiquitin-like protein modiﬁcation pathway also
regulates the function of Vif and/or Vpx–E3 complex11,41,42.
Thus, many signalling pathways may antagonize the function of
Vif or Vif–E3 complex to suppress Vif-mediated A3G
degradation. Since the activity of protein kinases or ubiquitin
ligases is basically regulated by the cellular context governed
by external or internal signals, these results suggest that
the functional interaction between viral accessary proteins and
host restriction factors can be, at least in part, regulated by
extracellular events.
ASK1 has been identiﬁed as MAP3K43 and is an effector of the
external stimuli-triggered signalling that induces apoptosis36.
Concordant with the role of ASK1 in virus infection, ASK1 is
involved in the apoptosis of cells infected by inﬂuenza A virus44.
Importantly, HIV-1 Nef is another ASK1-interacting protein that
suppresses tumour necrosis factor-a-induced cell death in HIV-1-
infected T-cell lines34. Although Kumar et al.45, using a luciferase
assay system, recently reported a dynamic interaction between
Nef and ASK1, this interaction was only marginally detectable in
our hands by conventional protein–protein interaction analysis.
Our current analyses demonstrate an alternative role for ASK1 in
HIV-1 infection, with ASK1 interacting with Vif and negatively
modulating the function of Vif in terms of E3 ligase activity.
Importantly, the kinase activity of ASK1 was found in our
analysis to be dispensable for Vif counteraction because (i) the
kinase-dead mutant of ASK1 could still inhibit Vif-mediated A3G
degradation, and (ii) Nef, a suppressor of ASK1 kinase activity,
did not affect the function of ASK1 directed against Vif. However,
a constitutively active ASK1 mutant (DN) seems to have a larger
inhibitory effect on Vif than its wild-type counterpart in cell-
based assays. This may be the result of a higher Vif-binding
afﬁnity of DN ASK1 compared with wild type. In fact, our data
show that ASK1 directly bound to the BC-box motif of Vif and
blocked the interaction between Vif and ELOB/C. Consequently,
assembly of the components of the Vif–E3 ubiquitin ligase
complex failed to degrade A3G. Our computational docking
simulation of the Vif–ASK1 interaction predicted that the binding
interface for ASK1 within Vif belongs to a conserved region that
is considered to be essential for formation of the E3 complex.
ASK1 may exploit this weak point of Vif to effectively suppress its
action.
We further found an unexpected ability of antiretroviral AZT
to restore antiviral immunity by suppressing Vif function via
ASK1. AZT is a chemical variant of the natural nucleoside
thymidine formed by the addition of an azido group, and is a
widely used nucleoside inhibitor that arrests reverse transcript
synthesis of viral DNA. AZT is transported to mitochondria46
and affects mitochondrial metabolism, causing mitochondrial
dysfunction that generates oxidative stress in cells47. This internal
stress may induce ASK1 to suppress the effects of Vif. Although
the pathway(s) underlying ASK1 induction following AZT
treatment are still unknown at present, ASK1 gene analysis in
future studies may elucidate the molecular mechanisms by which
ASK1 senses drugs.
In our current study, we mainly analysed the function of
overexpressed ASK1 in 293 cells and T-cell lines. Since ASK1 is
an apoptosis-regulating protein36,43, it is not expressed or is
expressed at very low levels in certain tissues and cells including
PBMC and T cells at steady state. Our current data demonstrate
that physiological concentrations of AZT stimulated the
expression of ASK1 in T cells in which the ability of Vif to
neutralize A3G was blocked (Fig. 5). Interestingly, this may not
reﬂect a general effect of ASK1 to repress ELOB/C-binding
proteins, since the activity of VHL was not impaired by ASK1
(Supplementary Fig. 2). While our study shows a distinct
polypharmacological effect of AZT, there are still many
unanswered questions about the physiological role and/or
clinical relevance of the ASK1–Vif interaction. To address these
important questions, longitudinal research and ﬁne-grained
assessment should be conducted in the future.
In conclusion, we here demonstrate that ASK1 is a novel Vif-
binding protein that negatively regulates Vif-mediated A3G
degradation. The interaction between HIV-1 accessory proteins
and host restriction factors is a potential target for the
development of new antiviral drugs. Understanding the molecular
mechanism of this interplay will provide new insights into the
preservation of the intrinsic antiviral system and may be useful
for the future therapeutic treatment of HIV infection.
Methods
Plasmids. Human MAP3Ks, ELOB/C, CUL5 and CBFb genes were ampliﬁed from
the Mammalian Gene Collection complementary DNA (cDNA) library and sub-
cloned into pcDNA-based vectors (Life Technologies, Gaithersburg, MD). The
accession codes for the genes used are listed in Supplementary Table 1. Hae-
magglutinin (HA)-tagged human ASK1 expression vector and its deletion mutants
(DN, DC, NT, KD, CT and K709M) have been described previously48–51. The
ASK1 cDNAs were inserted into the pcDNA4/HisMax vector (Life Technologies)
to obtain Xpress (XP)-tagged ASK1 or into the pRetroX-TRE3G vector (Clontech,
Palo Alto, CA) to generate retroviral vector. Plasmids encoding HIV-1NL4-3
Vif52,53, human A3G54 and ubiquitin55 have been described. The Vif mutants were
generated with PCR-based molecular cloning procedures. HIV-1NL4-3 Nef was
ampliﬁed from a pNL4-3 molecular clone56 and subcloned into p3xFLAG-CMV-
14 vector (Sigma-Aldrich, St Louis, MO). For in vitro protein synthesis, each cDNA
was subcloned into pEU vector (CellFree Sciences, Ehime, Japan).
Cells and viruses. HEK293, HEK293T (ATCC) and TZM-bl (NIH AIDS Reagent
Program) cells were maintained in DMEM supplemented with 10% fetal bovine
serum. CEM, CEMSS, H9, M8166 (NIH AIDS Reagent Program) and human
PBMCs (purchased from Kurabo, Osaka, Japan) were cultured in RPMI containing
10% fetal bovine serum. To generate CEM-TetON-ASK1 or CEMSS-TetON-ASK1
cells, parental cells were co-infected with VSV-G-pseudotyped retroviral vectors
expressing pRetroX-TRE3G-ASK1 and pRetroX-Tet3G (Clontech) and selected
with G418 and puromycin. HIV-1 stocks were produced by transient transfection
of HEK293T cells with the pNL4-3 (ref. 56) or AZT-resistant pNLGRINFQ
molecular clones (NIH AIDS Reagent Program). Culture supernatants containing
virus were collected at 48 h after transfection, ﬁltered through a 0.45-mm
Millex-HV ﬁlter (Merck Millipore, Billerica, MA) and immediately stored until use.
Ubiquitination and immunoprecipitation analysis. HEK293 cells in six-well
plates were transfected with vectors encoding XP-ASK1 (500 ng), HA-A3G (50 ng),
Vif (100 ng) and Myc-ubiquitin (500 ng). Cells were treated with 2 mM MG132
(a proteasome inhibitor, Sigma-Aldrich) for 18 h before being harvested. At 48 h
after transfection, cells were lysed with HBST buffer (10mM HEPES (pH 7.4),
150mM NaCl, 0.5% Triton-X-100) containing protease inhibitor Complete mini
(Roche Diagnostics, Basel, Switzerland). Cell lysates were immunoprecipitated with
EZview Red anti-HA Afﬁnity Gel (Sigma-Aldrich) or 2 mg of anti-Vif antibody
(Clone #319; NIH AIDS Reagent Program)57–59 mixed with protein G sepharose
(GE Healthcare, Healthcare, Little Chalfont, UK) and bound proteins were
analysed by western blotting as follows. Samples were loaded onto 10% or 3–15%
gradient gels and blotted onto PVDF membranes (Merck Millipore). Membranes
were probed with primary antibodies and horseradish peroxidase-conjugated
secondary antibodies (GE Healthcare). The antibodies used including dilutions are
listed in Supplementary Table 2. The proteins detected were visualized on a
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FluorChem digital imaging system (Alpha Innotech, San Leanardo, CA) and the
band intensities were quantiﬁed with NIH ImageJ software.
AlphaScreen and pull-down assays. The wheat germ cell-free protein production
with pEU vectors and AlphaScreen analysis has been described previously60–62. In
brief, DNA templates containing a biotin-ligating sequence or FLAG epitope were
ampliﬁed by split-PCR with pEU-based vectors and corresponding primers and
then used with the GenDecoder protein production system (CellFree Sciences). In
this study, Vif proteins were co-expressed with untagged CBFb to stabilize the
conformation of Vif protein28,63. For the in vitro competitive pull-down assays,
recombinant biotinylated Vif was pre-mixed with untagged ASK1 at a molar ratio of
1:1, 1:2, 1:4 or 1:8 for 5min at room temperature and then mixed with equivalent
amounts of FLAG-tagged CUL5, ELOB and ELOC proteins. After 1 h at 26 C, the
mixture was processed for pull-down with streptavidin-coated magnetic beads
(Merck Millipore). Bound proteins were detected with western blot analysis.
Transfection-based single-round infection assays. HEK293 cells in six-well
plates were cotransfected with pNL4-3DEnv-GFP or pNL4-3DEnvDVif-GFP (1 mg)
and with vectors encoding VSV-G (400 ng), ASK1 (250 ng) and A3G (25 ng) and
cultured for 2 days. The culture supernatants and cell lysates were subjected to
western blotting analysis. The p24 antigens in supernatants were measured with an
ELISA kit (Zepto Metrix, Buffalo, NY), and M8166 cells were infected with nor-
malized viruses (1 or 5 ng of p24 antigen) in 24-well plates for 24 h. Infectivity was
calculated by counting the numbers of GFP-positive cells.
Multicycle replication assays. CEM, CEMSS or their derivative cells (105 cells)
were infected with HIV-1NL4-3 (50 ng of p24 antigen) with or without 1 mgml 1
Dox. Viral supernatants were collected periodically and p24 levels were measured
as described above. In AZT experiments, H9 cells (106 cells) were transfected with
200 pmol ASK1-targeted siRNA (HSS106458; Life Technologies) or control siRNA
using Neon nucleofection system (Life Technologies) at 48 h before infection. Cells
were then infected with 50 ng of AZT-resistant HIV-1NLGRINFQ. After 2 days, cells
were washed four times with PBS and then treated with 10 mM AZT (Sigma-
Aldrich) for 24 h. The culture supernatants and cell lysates were then harvested and
subjected to western blotting or infectivity analysis. Infectivity was calculated by
measuring LTR-driven luciferase activity of TZM-bl indicator cells infected with
normalized viruses.
G-to-A hypermutation assays. Cellular DNA from HIV-infected cells was
extracted with a QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands) according
to the manufacturer’s instructions. The extracted DNA was ampliﬁed using a
primer pair HIV-1F (50-AGGCAGCTGTAGATCTTAGCCACTT-30) and HIV-1R
(50-GGTCTGAGGGATCTCTAGTTAC-30) and cloned into pGEM-T vector
(Promega, Madison, WI). Eight clones containing a 650-bp DNA fragment (a
portion of nef and 30 long terminal repeat region) were sequenced and the numbers
of mutations in the viral genomes were analysed.
Protein structure prediction and docking simulation. The structure models for
the CT domain of human ASK1 (ASK1 CT; 955–1,374 amino acids) were obtained
by I-TASSER software v2.1 (refs 64,65) or Molecular Operating Environment
software using templates (such as PDB accession codes 1OQY, 1IQC and 1QBK)
for the structural assembly simulations. To obtain the docking structure of Vif
(PDB accession code 4N9F) and ASK1 CT, we used the docking simulation server
ClusPro 2.0 (refs 66,67).
Statistical analysis. All graphs present the mean and s.d. The statistical sig-
niﬁcance of differences between two groups was tested by two-tailed unpaired t-test
with Prism 6 software (GraphPad, La Jolla, CA). A P value of o0.05 was con-
sidered statistically signiﬁcant.
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